Search hospitals > Ohio > Newark
Newark Radiation Oncology
Claim this profileNewark, Ohio 43055
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Stomach Cancer
Conducts research for Relapse
165 reported clinical trials
2 medical researchers
Summary
Newark Radiation Oncology is a medical facility located in Newark, Ohio. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Stomach Cancer, Relapse and other specialties. Newark Radiation Oncology is involved with conducting 165 clinical trials across 337 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and John P. Kuebler.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center6 years of reported clinical research
Expert in Skin Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
John P. KueblerStrecker Cancer Center-Belpre13 years of reported clinical research
Studies Fallopian Tube Cancer
Studies Peritoneal Carcinomatosis
1 reported clinical trial
5 drugs studied
Clinical Trials running at Newark Radiation Oncology
Breast Cancer
Lung Cancer
Skin Cancer
Cutaneous Melanoma
Bladder Carcinoma
Bladder Cancer
Multiple Myeloma
Non-Small Cell Lung Cancer
Melanoma
Pancreatic Cancer
Cognitive Training
for Breast Cancer Survivors
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Recruiting1 award N/A5 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Marker-Directed Monitoring
for Breast Cancer
This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Newark Radiation Oncology?
Newark Radiation Oncology is a medical facility located in Newark, Ohio. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Stomach Cancer, Relapse and other specialties. Newark Radiation Oncology is involved with conducting 165 clinical trials across 337 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and John P. Kuebler.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.